A Phase 1b, Double-Blind, Crossover Study of BHV-7000 in Patients With Inherited Erythromelalgia (IEM) With NaV1.7 Gain of Function Mutations
Latest Information Update: 23 Jan 2026
At a glance
- Drugs Opakalim (Primary)
- Indications Erythromelalgia
- Focus Therapeutic Use
- Sponsors Biohaven Therapeutics
Most Recent Events
- 20 Jan 2026 Status changed from not yet recruiting to recruiting.
- 08 Dec 2025 New trial record